Overview of Treatment Trials: Early Baseline Clinical and MRI Data of the PROMiSe Trial

  • J. S. Wolinsky
  • P. A. Narayana
  • R. He
Part of the Topics in Neuroscience book series (TOPNEURO)


Primary progressive multiple sclerosis (PPMS) is the least common clinical disease phenotype exhibited by MS patients. Current international consensus definitions of the various disease phenotypes demand that patients with PPMS have a progressive disease from onset and a clinical course without discernible attacks [1]. Some minor amount of improvement or worsening is allowed, but episodes that fit most modern trial definitions of acute relapses eliminate patients from this subtype and consign them to either secondary progressive or progressive relapsing MS categories, depending upon whether the attack occurred prior to or following the onset of their progressive neurologic dysfunction. Approximately 15% of MS patients have a progressive disease at onset, but nearly one-third of these will experience a clinical relapse. Thus, only 10% of all MS patients have PPMS. It is likely that some of these patients fail to recall remote episodes of neurologic dysfunction that may or may not have been attended by physicians or resulted in a formal diagnosis. Such cases of cryptic secondary progressive or “transitional” MS [2] may contaminate to some extent any cohort of rigorously defined PPMS patients. Further complicating our understanding of this clinical phenotype is the common use of the term “chronic progressive MS” to describe patient cohorts with secondary progressive, progressive relapsing, or PPMS.


Expand Disability Status Scale Glatiramer Acetate Cerebral Spinal Fluid Expand Disability Status Scale Score Primary Progressive Multiple Sclerosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46:907–911Google Scholar
  2. 2.
    Stevenson VL, Miller DH, Rovaris M et al (1999) Primary and transitional progressive MS: a clinical and MRI cross-sectional study. Neurology 52:839–845PubMedGoogle Scholar
  3. 3.
    Poser CM, Paty DW, Scheinberg L et al (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227–231PubMedCrossRefGoogle Scholar
  4. 4.
    European Study Group on interferon beta-1b in secondary progressive MS (1998) Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 352:1491–1497CrossRefGoogle Scholar
  5. 5.
    Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-la in MS (SPECTRIMS) Study Group (2001) Randomized controlled trial of interferon-beta-la in secondary progressive MS: Clinical results. Neurology 56:1496–1504Google Scholar
  6. 6.
    Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452PubMedGoogle Scholar
  7. 7.
    Weinshenker BG, Bass B, Rice GP et al (1989) The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 112:133–146Google Scholar
  8. 8.
    Cottrell DA, Kremenchutzky M, Rice GP et al (1999) The natural history of multiple sclerosis: a geographically based study. 6. Applications to planning and interpretation of clinical therapeutic trials in primary progressive multiple sclerosis. Brain 122:641–647 9.PubMedCrossRefGoogle Scholar
  9. Bornstein MB, Miller A, Slagle S et al (1991) A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology 41:533–539PubMedGoogle Scholar
  10. 10.
    McDonnell GV, Hawkins SA (1998) Clinical study of primary progressive multiple sclerosis in Northern Ireland, UK. J Neurol Neurosurg Psychiatry 64:451–6454Google Scholar
  11. 11.
    Thompson AJ, Montalban X, Barkhof F et al (2000) Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol 47:831–835PubMedCrossRefGoogle Scholar
  12. 12.
    McDonald WI, Compston A, Edan G et al (2001) Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 50:121–127Google Scholar
  13. 13.
    Thompson AJ, Polman CH, Miller DH et al (1997) Primary progressive multiple sclerosis. Brain 120:1085–1096PubMedCrossRefGoogle Scholar
  14. 14.
    Cottrell DA, Kremenchutzky M, Rice GP et al (1999) The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain 122:625–639Google Scholar
  15. 15.
    Bedell BJ, Narayana PA, Wolinsky JS (1997) A dual approach for minimizing false lesion classifications on magnetic resonance images. Magn Reson Med 37:94–102PubMedCrossRefGoogle Scholar
  16. 16.
    Wolinsky JS, Narayana PA, Noseworthy JH et al (2000) Linomide in relapsing and secondary progressive MS: part II: MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide Investigators. Neurology 54:1734–1741Google Scholar
  17. 17.
    Wolinsky JS, Narayana PA, Johnson KP, and the Copolymer 1 Multiple Sclerosis Study Group and the MRI Analysis Center (2001) United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Mult Scler 7:33–41Google Scholar
  18. 18.
    Noseworthy JH, Wolinsky JS, Lublin FD et al (2000) Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators. Neurology 54:1726–1733Google Scholar
  19. 19.
    Filippi M, Rovaris M, Gasperini C et al (1998) A preliminary study comparing the sensitivity of serial monthly enhanced MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in primary progressive multiple sclerosis. J Neuroimaging 8:88–93PubMedGoogle Scholar
  20. 20.
    Rovaris M, Comi G, Rocca MA et al (1999) Relevance of hypointense lesions on fast fluid-attenuated inversion recovery MR images as a marker of disease severity in cases of multiple sclerosis. Am J Neuroradiol 20:813–820PubMedGoogle Scholar
  21. 21.
    van Waesberghe JH, Castelijns JA, Weerts JG et al (1996) Disappearance of multiple sclerosis lesions with severely prolonged T1 on images obtained by a FLAIR pulse sequence. Magn Reson Imaging 14:209–213PubMedCrossRefGoogle Scholar
  22. 22.
    Filippi M, Wolinsky JS, Sormani MP, Comi G, European Canadian Glatiramer Acetate Study Group (2001) Enhancement frequency decreases with increasing age in relaps-ing-remitting multiple sclerosis. Neurology 56:422–423PubMedGoogle Scholar
  23. 23.
    Andersson PB, Waubant E, Gee L, Goodkin DE (1999) Multiple sclerosis that is progressive from the time of onset: clinical characteristics and progression of disability. Arch Neurol 56:1138–1142PubMedCrossRefGoogle Scholar
  24. 24.
    Bashir K, Whitaker JN (1999) Clinical and laboratory features of primary progressive and secondary progressive MS. Neurology 53:765–771PubMedGoogle Scholar
  25. 25.
    McDonnell GV, Hawkins SA (1996) Primary progressive multiple sclerosis: a distinct syndrome? Mult Scler 2:137–141PubMedGoogle Scholar
  26. 26.
    Leary SM, Stevenson VL, Miller DH, Thompson AJ (1999) Problems in designing and recruiting to therapeutic trials in primary progressive multiple sclerosis. J Neurol 246:562–568PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia, Milano 2002

Authors and Affiliations

  • J. S. Wolinsky
  • P. A. Narayana
  • R. He

There are no affiliations available

Personalised recommendations